Recro Pharma eliminates 50 jobs following FDA setback

Recro Pharma Inc. is eliminating about 50 positions in its acute care segment, and seeking a partner to commercialize its lead new drug candidate. Both moves come about two weeks after the Food and Drug Administration for a second time turned down the Malvern, Pa, pharmaceutical company's new drug application for intravenous meloxicam. Recro is seeking to market IV meloxicam, a non-opioid, as a treatment to manage moderate-to-severe pain. The company, which also operates a revenue-generating contract…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news